WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
Deals and Financings
- WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage;
- Shenzhen Hepalink announced a $69 million investment into Canada’s Resverlogix that will raise its stake in Resverlogix to 45%;
- Eargo, a Silicon Valley hearing aid company, closed the first tranche of a $45 million Series C round, led by Hong Kong’s Nan Fung Life Sciences Fund
- Prenetics Limited raised $40 million to expand its pan-Asia DNA testing service aimed at individuals;
- Huawei and Philips announced a China cloud healthcare partnership that uses AI to deliver best diagnostic practices and monitoring to second tier China cities;
- GIMDx of Carlsbad, California acquired exclusive China OEM and distribution rights to oncology diagnostic products made by IncellDx, a Menlo Park company;
Trials and Approvals
- CStone of Suzhou dosed the first patient in a Phase I trial of its anti-PD-L1 monoclonal antibody, reaching the clinic in under two years,
- Chi-Med and AstraZeneca presented positive safety and efficacy data of their partnered drug, the c-MET inhibitor savolitinib;
- FibroGen, a US-China biopharma, reported the CFDA accepted an NDA to review its novel anemia treatment for China approval.
